In partnership with Synergy Enterprises, Inc., Lexicon & Line will support DEA prevention outreach and community ...

Lexicon has installed a new advanced robotics welding line at its Prospect Steel division in Blytheville, making the company ...

Three weeks after taking over as CEO of Lexicon Pharmaceuticals back in 2024, Michael Exton suggested the company close its ...

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 4th Annual H.C. Wainwright BioConnect Investor Conference, taking place ...

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its first quarter 2026 financial results on Thursday, May 7, 2026, prior to market open. Management will conduct a ...

SONATA-HCM anticipated to be fully enrolled mid-2026 Resubmission of NDA for ZYNQUISTA ® in type 1 diabetes anticipated mid-2026 with potential ...

Q1 2026 Management View “We began this year with an ambitious set of 2026 objectives, which are to: firstly, advance our late-stage regulatory programs, both of which have major potential milestones ...

Sanofi has terminated a nearly four-year-old, potentially $1.7 billion-plus collaboration with Lexicon Pharmaceuticals to develop ZynquistaTM (sotagliflozin) for type 1 and type 2 diabetes after the ...

Lexicon Pharmaceuticals won't take no for an answer. The Texas pharma—convinced of the value of its diabetes candidate sotagliflozin—has clapped back at its latest rejection from the FDA, asking to be ...

It’s been a winding road full of potholes, but Lexicon Pharmaceuticals has finally reached its destination, gaining an FDA approval for Inpefa (sotagliflozin). The once-daily pill becomes the first ...

An explosion in data volumes, proliferation of platforms, and evolving regulatory requirements has made effective monitoring of employee communications much more difficult. The remote and hybrid ...